Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00971815
Other study ID # M-20080132
Secondary ID
Status Completed
Phase N/A
First received June 2, 2009
Last updated June 2, 2017
Start date May 2009
Est. completion date April 2014

Study information

Verified date May 2013
Source University of Aarhus
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic stress has been proposed to be involved the development of western life-style diseases such as cardiovascular disease and type 2 diabetes (T2DM). At the same time chronic stress is also believed to cause psychiatric disease such as melancholic depression (MD)and anxiety disorders.

Accordingly, humans born with low birth weight (LBW) (ei. less than 5,0 LB) display an increased risk for T2DM and MD. Studies suggest stress and adrenal stress hormones (glucocorticoids) (GCC) might be involved in the development of both of these conditions.

Recent studies of animals born LBW suggest, that SSRI-compounds, usually employed in the treatment of MD-related diseases, reduces stress-responses and levels of stress hormones such adrenal steroids and at the same time has a positive influence on glucose metabolism.

In present study, the investigators aim to measure levels of GCC and stress and assess glucose metabolism in healthy young men (20-35 years) born LBW (40 subjects). The volume and structure of a certain brain area (ie. hippocampus) involved in regulation of adrenal GCC and known to be malfunctioning in chronically stressed individuals will be assessed by magnetic resonance imaging (MRI). Further metabolic examination will be accompanied by MRI spectroscopy of liver and muscle fat content as well as total fat content (Dexa-scanning) and contents of fat in the abdomen (by MRI) . Psychiatric well-ness and symptoms will be characterized by well-established questionnaires such as MDI and SCL-92 and responses as regards blood pressure, heart rate and changes in basal plasma concentrations of GCC and Epinephrine will be assessed while performing a Stroop Stress Test. Finally, a 24 hour blood pressure profile test will be included.

After this extensive examination program, subjects will be randomized to 3-4 months of treatment with either Escitalopram (an SSRI-compound) or Placebo. Subsequently, at the end of the treatment, the whole examination program will be repeated to detect potential beneficial changes.

A group of young normal birth weight men (20 subjects) will serve as a healthy baseline group for comparison and will not be exposed to any medical treatment.

This trial will add understanding to the mechanism underlying the development of type 2 diabetes and depression in LBW. Additionally, present trial might be capable of proposing a novel treatment strategy to prevent the development of these diseases in LBW man.


Recruitment information / eligibility

Status Completed
Enrollment 60
Est. completion date April 2014
Est. primary completion date September 2011
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 20 Years to 35 Years
Eligibility Inclusion Criteria:

1. Healthy men 20-35 years old.

2. birth weight <2500g.

3. Born at gestational week 38- 40 (42).

Exclusion Criteria:

1. Diabetes, insulin-resistance or precursors in first degree relatives or maternal gestational diabetes.

2. Small parents(mother <160cm and/or father <170cm).

3. History of abuse of alcohol, medicine og drugs in the mother during pregnancy.

4. Liver of renal failure : s-ALAT > 2.5 normal upper limit (>175µM) or s-creatinine >125 µmol/l.

5. Co-morbidity that after at medical examination is considered to be a problem.

6. BMI>25.5

7. Smoking that is considered to be an issue as regards completing the study.

8. Treatment with a MAO-inhibitor.

9. Born before gestational week 38.

10. Participation in larger X-ray examinations such CT-scans during the last 12 months.

11. Participation in medical experiments or treatments involving intravenous administration of radioactive substances during the last

12. Ongoing medical treatment that will be considered a issue for completing the study.

13. Allergy towards the substance Escitalopram.

14. Metal parts in the body that contra-indicates MRI.

15. Ongoing medical treatment thrombocyte inhibiting substances such as NSAIDS.

16. Previous gastrointestinal bleeding or gastro-duodenal ulcers.

17. Depression during examination or treatment

16/05-2011: Criterias updated - added 17 and adjusted 6. from BMI >25 to BMI >25.5

Study Design


Intervention

Drug:
Escitalopram
first week: 10mg/day. Then, treatment with 20mg/day is continued throughout a 3 months period of time.
placebo
1/2 pill pr day first week, then 1 pill pr. day throughout a 3 months treatment period (90-118 ± 7days)

Locations

Country Name City State
Denmark Medical Dep M, Diabetes and Endocrinology Aarhus University Hospital, Aarhus Sygehus Aarhus

Sponsors (1)

Lead Sponsor Collaborator
University of Aarhus

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in rate of glucose dissappearance Changes in LBW-subjects from baseline vs. post-treatment after 3 months treatment with placebo or Escitalopram
Primary Changes in the 24-hour AUC of free plasma cortisol Changes in LBW-subjects from baseline vs. post-treatment after 3 months treatment with placebo or Escitalopram
Secondary 24 hour basal plasma cortisol/ACTH profile as measured every 3rd hour. before and after 3 months of treatment with placebo or Escitalopram
Secondary hippocampic volume and structure as assessed by MRI All limbic structures (amygdala, thalamus, hippocampus and ventromedial prefrontal cortex) were morphologically and volumetrically analyzed. before and after 3 months of treatment with placebo or Escitalopram
Secondary 24 hour bloodpressure profile before and after 3 months of treatment with placebo or Escitalopram
Secondary MRI spectroscopy of fat in skeletal muscle tissue Before and after 3 months of treatment with placebo or Escitalopram
Secondary MRI spectroscopy of fat in liver Before and after 3 months of treatment with placebo or Escitalopram
Secondary Abdominal fat as assessed by MRI Before and after 3 months of treatment with placebo or Escitalopram
Secondary MDI questionnaire scores Before and after 3 months of treatment with placebo or Escitalopram
Secondary SCL-92 questionnaire scores Before and after 3 months of treatment with placebo or Escitalopram
Secondary Fasting blood lipid profile Before and after 3 months of treatment with placebo or Escitalopram
Secondary Ratio between insulin and glucose concentrations in blood during an oral glucose tolerance test (OGTT) Before and after 3 months of treatment with placebo or Escitalopram
Secondary Whole body fat content as assessed by a dexa scanning Before and after 3 months of treatment with placebo or Escitalopram
Secondary Hepatic insulin sensitivity as assessed suppression of endogenous glucose production (calculated by infusion of 3H-labelled glucose) Before and after 3 months of treatment with placebo or Escitalopram
Secondary 10 pm to midnight basal plasma ACTH/cortisol concentration ratio as measured by blood sampling every 10th minute. Before and after 3 months of treatment with placebo or Escitalopram
Secondary increase in blood pressure and heart rate during Stroops Stress test Before and after 3 months of treatment with placebo or Escitalopram
Secondary Increase in plasma ACTH, cortisol and epinephrine concentrations during Stroops Stress Test before and after 3 months of treatment with placebo or Escitalopram
Secondary SRPAS questionnaire scores Self Reported Physical Activity Questionaire Before and after 3 months of treatment with placebo or Escitalopram
Secondary Actigraph GT3X activity monitoring Objective measurements of physical activity in 96 hours at home Before and after 3 months of treatment with placebo or Escitalopram
Secondary Whole body bone mass density and T-/Z-scores as assessed by a dexa scanning Before and after 3 months of treatment with placebo or Escitalopram
Secondary Plasma-Inflammation markers Before and after 3 months of treatment with placebo or Escitalopram
See also
  Status Clinical Trial Phase
Completed NCT05219994 - Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum N/A
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Completed NCT02284893 - Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone Phase 3
Completed NCT04274660 - Evaluation of Diabetes and WELLbeing Programme N/A
Active, not recruiting NCT05887817 - Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR) Phase 4
Active, not recruiting NCT05566847 - Overcoming Therapeutic Inertia Among Adults Recently Diagnosed With Type 2 Diabetes N/A
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Completed NCT04965506 - A Study of IBI362 in Chinese Patients With Type 2 Diabetes Phase 2
Recruiting NCT06115265 - Ketogenic Diet and Diabetes Demonstration Project N/A
Active, not recruiting NCT03982381 - SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes Phase 4
Completed NCT04971317 - The Influence of Simple, Low-Cost Chemistry Intervention Videos: A Randomized Trial of Children's Preferences for Sugar-Sweetened Beverages N/A
Completed NCT04496154 - Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood N/A
Completed NCT04023539 - Effect of Cinnamomum Zeylanicum on Glycemic Levels of Adult Patients With Type 2 Diabetes N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05530356 - Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
Completed NCT03960424 - Diabetes Management Program for Hispanic/Latino N/A
Completed NCT04097600 - A Research Study Comparing Active Drug in the Blood in Healthy Participants Following Dosing of the Current and a New Formulation (D) Semaglutide Tablets Phase 1
Completed NCT05378282 - Identification of Diabetic Nephropathy Biomarkers Through Transcriptomics
Active, not recruiting NCT06010004 - A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Phase 3
Completed NCT03653091 - Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes N/A